Human Biosystems geht steil 200%

Human Biosystems wird in kürze steil nach oben schiessen.

Hier die Gründe

1. Volumen nimmt immer mehr zu. Beachtet vorallem den Chart von heute in Frankfurt ist zu sehen, wahrscheinlich jemand genau weiss was bevorsteht. Bei 0,84€ wurden 185.000 Stück gekauft. Da hat mal eben einer 15.000€ investiert. Bei 8 Cent nochmals 50.000 Stück. Weitere 4000€.

2. Bald kommt das fünfte Patent (bisher ist es nur angekündigt. Wenn es tatsächlich kommt, werden wir die Nachwehen von der Kursexplosion von der dritten Januarwoche sehen.

3. Joint Venture mit Ethanolfabrik kommt langsam ins Rollen: http://www.faz.net/d/invest/meldung.aspx?id=41772490

4. Durchlesen, bescheidwissen http://www.finanznachrichten.de/...ichten-2007-02/artikel-7813382.asp

Meine Meinung: Wer morgen mit 1000 bis 3000 reingeht, der wird seine Posten nicht unter 12-15 Cent verkaufen müssen.

Seht es euch mal an, ich denke vorallem die derben Zukäufe (oben genannte Trades) deuten darauf hin, dass jemand sehr grosses Vertrauen in den Wert hat ;-)))  

 

Bei Punkt 1 meinte ich 0,084€ nicht 0,84€.  

Heute trifft wohl jeder Kauf auf "Gegen den Trend laufen" zu. ;-)  

und Ethanol herstellen sind doch 2 völlig verschiedene Sachen. Klappt's mit der einen Sache net, versuch'ich halt was anderes, oder so ähnlich???  

Die Ethanolgeschichte dient als zweites Standbein, gehört aber zu 100% an Human Biosystems. Hier gibts infos: http://www.humanbiosystems.com/hbs_bio_energy.htm

..Weiss garnicht was daran so funny sein soll? *kopfschüttel*  

MARCH 20, 2007 - 07:00 ET  

Human BioSystems Opens New Cellular Biology Facility

PALO ALTO, CALIFORNIA--(CCNMatthews - March 20, 2007) - Human BioSystems ("HBS" or "Company") (OTCBB:HBSC), announced in September that it had signed a 5 year lease on a new R&D facility near its current location in Vicksburg, Michigan.

The Company announced today that it has moved into its new laboratory facility. This facility will enable HBS researchers to extend their preservation studies from whole organs to tissues and cells, and to insure that all work is carried out in a modern state-of-the-art scientific environment.

"We now have the facility to perform not only elaborate microsurgical techniques but also to culture cells and tissues and study them at the molecular level," stated Dr. Luis Toledo, HBS' Chief Medical Officer.

Dr. David Winter, President of HBS further explained that "This facility will allow us to expand our work in preservation technology that we have been developing since 2002. We will have the ability to control important variables so that we can directly study tissue and cell preservation. We are particularly interested in prolonging activity and function in tissues and cells such as stem cells and pancreatic islet cells."

Some of the projects that the Company is considering for the new facility include:

- Investigating how HBS preservation technology is superior to other technologies and how it can be further improved.

- Characterizing the cellular and molecular basis for diseases such as diabetes with potential cure through organ, tissue or cell transplantation.

- Developing improved animal and cellular models (including stem cell technology) for the study of immuno-tolerance and immune response after transplantation.

- Assessing the effectiveness of proposed preservation and transplant technology in the treatments for end-stage organ diseases.

Human BioSystems is a developer of preservation platforms for donor organs, blood platelets and other biomaterials. The Company, which is headquartered in Palo Alto, California has research facilities in Michigan.

Certain statements contained herein are "forward-looking'' statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, results from ongoing research and development as well as clinical studies, failure to obtain regulatory approval for the Company's products, if required, failure to develop a product based on the Company's technology, failure of any such products to compete effectively with existing products, the inability to find a strategic partner or to consummate a relationship with a potential strategic partner on acceptable terms, and other factors discussed in filings made by the Company with the Securities and Exchange Commission.

 

Ich denke Human BioSystems steht langsam in den Starlöcher zur
großen Aufholjagd
Kurse zw. 20-30 cent
also 300-400% sind drin
Mfg